Online citations, reference lists, and bibliographies.
← Back to Search

Improved Delivery Of Angiogenesis Inhibitors From PLGA:poloxamer Blend Micro- And Nanoparticles

I. D'angelo, Yolanda Parajó, A. Horváth, G. Keri, M. L. La Rotonda, M. Alonso
Published 2010 · Medicine, Materials Science

Cite This
Download PDF
Analyze on Scholarcy
Share
Clinical studies have demonstrated the efficacy of new strategies in cancer therapy, such as chemotherapy and radiotherapy, associated to the administration of tumour vascularization inhibitors. A critical limitation for the clinical application of angiogenesis inhibitors relies in their instability in biological environment and high-dose requirements. This work has attempted to overcome this limitation by designing an adequate delivery vehicle consisting of PLGA:poloxamer blend micro- and nanoparticles. The potential of this delivery system was investigated for a new synthetic angiogenesis inhibitor named polyaminoacid JS-2892b. PLGA:poloxamer (ratio 10 : 1) blend microparticles were prepared by the oil-in-oil emulsion technique, while PLGA:poloxamer (ratio 1 : 1) blend nanoparticles were obtained by a modified solvent diffusion technique. The results showed that, by adjusting the formulation conditions, it was possible to efficiently encapsulate the polyaminoacid JS-2892b within PLGA:poloxamer micro- (particle size of 20 µm and encapsulation efficiency higher than 90%) and nanoparticles (particle size of less than 280 nm and encapsulation efficiency of 52%). In addition, the delivery of the polyaminoacid JS-2892b from the particles could be controlled, without altering its stability, for extended periods of time (from a few days to over a month). The release of the encapsulated compound was significantly affected by the particle size and the way the drug is dispersed into the polymeric matrix. Therefore, this study provides information about the formulation conditions and potential of biodegradable particles for the controlled release of polyaminoacid JS-2892b.
This paper references
10.1163/1568562041753098
Design and characterisation of new nanoparticulate polymer blends for drug delivery
N. Csaba (2004)
10.1208/pt070361
Formulation of anastrozole microparticles as biodegradable anticancer drug carriers
A. Zidan (2008)
10.1002/PSC.969
Controlled disassembly of peptide amphiphile fibres
D. W. Löwik (2008)
10.1016/0168-3659(94)90026-4
The influence of biodegradable microcapsule formulations on the controlled release of a protein
H. Sah (1994)
Microencapsulation of antigens using biodegradable polyesters: facts and phantasies.
T. Kissel (1997)
10.1007/BF02980037
Control of encapsulation efficiency and initial burst in polymeric microparticle systems
Yoon Yeo (2004)
10.1016/J.CPLETT.2008.12.031
Preparation and size optimisation of silica nanoparticles using statistical analyses
G. Davies (2009)
10.1021/BM049577P
PLGA:poloxamer and PLGA:poloxamine blend nanoparticles: new carriers for gene delivery.
N. Csaba (2005)
10.1056/NEJM197111182852108
Tumor angiogenesis: therapeutic implications.
J. Folkman (1971)
10.1177/1534735405285562
Targeting Angiogenesis With Integrative Cancer Therapies
D. Yance (2006)
10.1016/0140-6736(93)90902-S
Angiogenesis
A. Logan (1993)
10.1016/S0753-3322(05)80070-8
Tumor angiogenesis and therapy.
Y. Cao (2005)
10.1016/J.JCONREL.2006.03.017
PLGA:poloxamer and PLGA:poloxamine blend nanostructures as carriers for nasal gene delivery.
N. Csaba (2006)
10.1016/J.EJPB.2007.02.016
Comparative study of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods.
F. Tewes (2007)
10.1002/JPS.1106
Stabilization of a model formalinized protein antigen encapsulated in poly(lactide-co-glycolide)-based microspheres.
W. Jiang (2001)
Effect of somatostatin drived peptides and peptidomimetics on neurogenic inflammation
J di (2008)
10.1200/JCO.2000.18.13.2593
Activity of thalidomide in AIDS-related Kaposi's sarcoma.
R. Little (2000)
10.1023/A:1007582911958
Visual Evidence of Acidic Environment Within Degrading Poly(lactic-co-glycolic acid) (PLGA) Microspheres
K. Fu (2004)
10.1016/J.JCIS.2006.07.031
Colloidal stability of pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms.
M. J. Santander-Ortega (2006)
10.1016/S0378-5173(99)00422-6
Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique.
A. Lamprecht (2000)
10.1016/j.jconrel.2007.11.017
Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice.
Naoyuki Murata (2008)
10.2217/17435889.1.1.17
Nanotechnology for antiangiogenic cancer therapy.
H. Kobayashi (2006)
10.1016/S0378-5173(99)00178-7
Formulation strategies for the stabilization of tetanus toxoid in poly(lactide-co-glycolide) microspheres.
A. Sánchez (1999)
10.1038/sj.onc.1204121
Design of growth factor antagonists with antiangiogenic and antitumor properties
S. Sebti (2000)
Novel peptides and amino acid derivatives, pharmaceutical
A Horváth (2007)
10.1023/A:1018820507379
A Novel System Based on a Poloxamer/ PLGA Blend as a Tetanus Toxoid Delivery Vehicle
M. Tobío (2004)
10.1056/NEJM197108122850711
Transplacental carcinogenesis by stilbestrol.
J. Folkman (1971)
10.2174/187152006778699130
Recent developments in polymeric nanoparticle engineering and their applications in experimental and clinical oncology.
S. Moghimi (2006)
10.1016/J.BBAGEN.2004.10.005
Peptides and hydrolysates from casein and soy protein modulate the release of vasoactive substances from human aortic endothelial cells.
R. Ringseis (2005)
Novel peptides and amino acid derivatives , pharmaceutical compositions containing same and the use of these compounds
A Horváth (2007)
10.1016/S0168-3659(00)00339-4
Biodegradable polymeric nanoparticles as drug delivery devices.
K. Soppimath (2001)
10.1021/JS9604117
A theoretical model of erosion and macromolecular drug release from biodegrading microspheres.
R. Batycky (1997)
10.1080/02652040500162659
Effect of cryoprotectants on the reconstitution of surfactant-free nanoparticles of poly(DL-lactide-co-glycolide)
Y-I Jeong (2005)
10.1006/MVRE.2001.2354
Effect of HGF-like basic hexapeptides on angiogenesis.
K. Fazekas (2001)
10.1016/0022-1759(83)90303-4
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
T. Mosmann (1983)
10.1016/S1357-2725(01)00023-1
Endogenous angiogenesis inhibitors and their therapeutic implications.
Y. Cao (2001)
10.1016/S0939-6411(98)00011-3
Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants.
D. Blanco (1998)
10.1016/S0092-8674(00)81848-6
Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth
M. O'reilly (1997)
Novel peptides and amino acid derivatives
A Horváth (2007)
10.1016/S0928-0987(03)00019-8
Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha.
A. Sánchez (2003)
10.1038/nature04483
Angiogenesis as a therapeutic target
N. Ferrara (2005)
10.1016/S0168-3659(01)00430-8
Non-aqueous encapsulation of excipient-stabilized spray-freeze dried BSA into poly(lactide-co-glycolide) microspheres results in release of native protein.
K. G. Carrasquillo (2001)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar